CSTL (Castle Biosciences) LT-Debt-to-Total-Asset: 0.06 (As of Mar. 2026)

What is Castle Biosciences LT-Debt-to-Total-Asset?

Castle Biosciences CSTL +6.07% 73 LT-Debt-to-Total-Asset is 0.06 as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Castle Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.06.

Castle Biosciences's long-term debt to total assets ratio increased from Mar. 2025 (0.05) to Mar. 2026 (0.06). It may suggest that Castle Biosciences is progressively becoming more dependent on debt to grow their business.

Castle Biosciences (NAS:CSTL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Castle Biosciences LT-Debt-to-Total-Asset Related Terms

Castle Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences LT-Debt-to-Total-Asset Chart

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.05

0.06

Castle Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.06	0.06	0.06	0.06

73GF Score

Castle Biosciences Inc CSTL

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Castle Biosciences LT-Debt-to-Total-Asset Calculation

Castle Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	35.171	/	578.556
	=	0.06

Castle Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	33.803	/	547.805
	=	0.06

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.06 mean?

Castle Biosciences (CSTL) has a LT-Debt-to-Total-Asset of 0.06 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Castle Biosciences and its competitors.

Is Castle Biosciences' LT-Debt-to-Total-Asset too high?

Castle Biosciences' current LT-Debt-to-Total-Asset is 0.06. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Castle Biosciences' LT-Debt-to-Total-Asset compare to FLGT and MYGN?

Castle Biosciences' LT-Debt-to-Total-Asset of 0.06 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current LT-Debt-to-Total-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Castle Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.21 — trading 17% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.06. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current LT-Debt-to-Total-Asset is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.21 is trading 17% below its estimated GF Value™ of $29.16. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

LT-Debt-to-Total-Asset: 0.06
GF Value™: $29.16 vs. price of $24.21 (17% below fair value)
GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies FLGT MYGN OPK BDSX IMDX PSNL XGN BNR IDXG PRPO TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Other Exchanges 086:Germany

Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546

Website https://www.castlebiosciences.com

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

73GF Score

Get the complete analysis for CSTL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.21

Price

$29.16

GF Value

View CSTL Analysis

See LT-Debt-to-Total-Asset data for all stocks →